Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.

This joint announcement is for information purposes only and does not constitute, or form part of, an invitation or offer to acquire, purchase or subscribe for securities of Guanze Medical Information Industry (Holding) Co., Ltd. or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of securities of Guanze Medical Information Industry (Holding) Co., Ltd. in any jurisdiction in contravention of applicable laws or regulations. This joint announcement is not for release, publication or distribution in or into any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
富德(香港)投資控股有限公司
(Incorporated in Hong Kong with limited liability)

GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD.
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2427)

JOINT ANNOUNCEMENT
(1) CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY ARISTO SECURITIES LIMITED FOR AND ON BEHALF OF FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF GUANZE MEDICAL INFORMATION INDUSTRY (HOLDING) CO., LTD. (OTHER THAN THOSE ALREADY OWNED AND/OR AGREED TO BE ACQUIRED BY FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED, ITS ULTIMATE BENEFICIAL OWNERS AND PARTIES ACTING IN CONCERT WITH ANY OF THEM); (2) RESULTS OF THE OFFER; (3) SETTLEMENT OF THE OFFER; AND (4) PUBLIC FLOAT OF THE COMPANY

Financial adviser to the Offeror

Lego Corporate Finance Limited
力高企業融資有限公司

Financial adviser to the Company

越秀融資
YUE XIU CAPITAL

Independent Financial Adviser to the Independent Board Committee

軟庫中華 SBI China

Reference is made to (i) the joint announcements dated 11 February 2026 and 20 February 2026 in relation to the Offer; (ii) the joint announcements dated 4 March 2026 and 10 April 2026 in relation to the delay in despatch of composite document in relation to the Offer; and (iii) the composite document dated 17 April 2026 (the "**Composite Document**"), jointly issued by FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED (the "**Offeror**") and Guanze Medical Information Industry (Holding) Co., Ltd. (the "**Company**") in relation to the Offer. Unless otherwise defined, capitalised terms used in this joint announcement shall have the same meanings as those defined in the Composite Document.

CLOSE OF THE OFFER

The Offeror and the Company jointly announce that the Offer was closed at 4:00 p.m. on Friday, 8 May 2026 and was not revised or extended by the Offeror.

RESULTS OF THE OFFER

As at 4:00 p.m. on Friday, 8 May 2026, being the latest time and date for acceptance of the Offer as set out in the Composite Document, the Offeror had received two valid acceptances in respect of a total of 10,000 Shares under the Offer, representing approximately 0.001% of the entire issued share capital of the Company as at the date of this joint announcement.

Immediately after the close of the Offer and taking into account the two valid acceptances in respect of 10,000 Offer Shares under the Offer as at 4:00 p.m. on Friday, 8 May 2026 and subject to the due registration by the Registrar of the transfer of the Offer Shares in respect of which valid acceptances were received, the Offeror, its ultimate beneficial owners and parties acting in concert with any of them are interested in an aggregate of 699,174,575 Shares, representing approximately 73.6% of the entire issued share capital of the Company as at the date of this joint announcement.

SETTLEMENT OF THE OFFER

Based on the two valid acceptances in respect of 10,000 Offer Shares under the Offer at the Offer Price of HK$0.25 per Offer Share, the total consideration of the Offer is HK$2,500.

Remittances in respect of the cash consideration (after deducting the Hong Kong seller's ad valorem stamp duty in respect of acceptances of the Offer) payable for the Offer Shares tendered under the Offer have been/will be despatched to the Independent Shareholders accepting the Offer by ordinary post at their own risk as soon as possible, but in any event no later than seven (7) Business Days after the date of receipt of all relevant documents required to render such acceptance complete and valid in accordance with the Takeovers Code.

The latest date for posting remittances in respect of valid acceptances received under the Offer is Tuesday, 19 May 2026.

SHAREHOLDING STRUCTURE OF THE COMPANY

Immediately following Completion of the Acquisition of the 699,164,575 Sale Shares in aggregate from the Selling Shareholder pursuant to the Sale and Purchase Agreement and before the commencement of the opening for acceptance of the Offer on 17 April 2026, the Offeror, its ultimate beneficial owners and parties acting in concert with any of them held a total of 699,164,575 Shares, representing approximately 73.6% of the entire issued share capital of the Company.

Taking into account the two valid acceptances in respect of 10,000 Offer Shares under the Offer (representing approximately 0.001% of the entire issued share capital of the Company) and subject to the due registration by the Registrar of the transfer of the Offer Shares in respect of which valid acceptances were received, the Offeror, its ultimate beneficial owners and parties acting in concert with any of them are interested in an aggregate of 699,174,575 Shares, representing approximately 73.6% of the entire issued share capital of the Company as at the date of this joint announcement.

Save for the Sale Shares and the valid acceptances under the Offer as disclosed above, the Offeror, its ultimate beneficial owners and parties acting in concert with any of them (i) did not hold, own, control or have direction over any Shares or rights over Shares before the commencement of the Offer Period; (ii) had not acquired or agreed to acquire any Shares or any rights over Shares during the Offer Period; and (iii) had not borrowed or lent any relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) in the Company during the Offer Period and up to and including the date of this joint announcement.

The following table sets out the shareholding structure of the Company (i) immediately before Completion; (ii) immediately following Completion and before the commencement of the Offer Period; and (iii) immediately upon the close of the Offer (assuming that the transfer to the Offeror of those Offer Shares acquired by the Offeror under the Offer has been completed) and as at the date of this joint announcement:

Shareholders	**Immediately before Completion**		**Immediately following Completion and before the commencement of the Offer Period**		**Immediately upon the close of the Offer (assuming that the transfer to the Offeror of those Offer Shares acquired by the Offeror under the Offer has been completed) and as at the date of this joint announcement**	
	Number of Shares	*Approximate % of issued Shares*	*Number of Shares*	*Approximate % of issued Shares*	*Number of Shares*	*Approximate % of issued Shares*
The Offeror and parties acting in concert with it						
— The Offeror *(Note 1)*	—	—	699,164,575	73.60	699,174,575	73.60
Selling Shareholder						
— Meng A Capital Limited *(Note 2)*	699,164,575	73.60	—	—	—	—
Public Shareholders	250,835,425	26.40	250,835,425	26.40	250,825,425	26.40
Total	**950,000,000**	**100.00**	**950,000,000**	**100.00**	**950,000,000**	**100.00**

Notes:

1. The Offeror is ultimately beneficially owned as to 94% by Mr. Cheung and as to 6% by Ms. Tao.

2. Meng A Capital Limited, a company incorporated in the British Virgin Islands, is legally and beneficially wholly owned by Mr. Meng. Mr. Meng is an executive Director and the chairman of the Board.

3. Save for Mr. Meng, who beneficially owned 699,164,575 Shares through Meng A Capital Limited immediately before Completion, none of the Directors held/holds any Shares and other relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) of the Company immediately before and following Completion and as at the date of this joint announcement.

PUBLIC FLOAT OF THE COMPANY

Immediately upon the close of the Offer and as at the date of this joint announcement, subject to the due registration by the Registrar of the transfer of the Offer Shares in respect of which valid acceptances were received, an aggregate of 250,825,425 Shares, representing approximately 26.4% of the entire issued share capital of the Company as at the date of this joint announcement, are held by the public (as defined under the Listing Rules).

In view of the above, the Company continues to satisfy the minimum public float requirement of 25% as set out in Rule 13.32B(1) of the Listing Rules.

By order of the board
FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED
Zhang, David Jia-yuan
Sole director

By order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Meng Xianzhen
Chairman and executive Director

Hong Kong, 8 May 2026

As at the date of this joint announcement, Mr. Zhang is the sole director of the Offeror. As at the date of this joint announcement, Mr. Cheung is the sole director of Shenzhen City Junde Investment Co., Ltd. (深圳市峻德投資有限公司), the ultimate parent company of the Offeror*

Each of the sole director of the Offeror (being Mr. Zhang) and the sole director of the ultimate parent company of the Offeror (being Mr. Cheung) jointly and severally accepts full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Group, the Selling Shareholder and its ultimate beneficial owner), and confirms, having made all reasonable enquiries, that to the best of his knowledge, opinions expressed in this joint announcement (other than those expressed by the Directors in their capacities as such) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement, the omission of which would make any statement in this joint announcement misleading.

As at the date of this joint announcement, the Board comprises Mr. Meng Xianzhen (Chairman) and Mr. Guo Zhenyu as executive Directors, Ms. Meng Cathy as non-executive Director, and Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this joint announcement (other than the information relating to the Offeror, the ultimate beneficial owners of the Offeror and the parties acting in concert with any of them), and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this joint announcement (other than those expressed by each of the sole director of the Offeror and the sole director of the ultimate parent company of the Offeror) have been arrived at after due and careful consideration and there are no other facts not contained in this joint announcement the omission of which would make any statement in this joint announcement misleading.

In the event of any inconsistency, the English text of this joint announcement shall prevail over its Chinese text.

* *For identification purpose only*